Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Prospective Randomized Comparison of Zymar(Gatifloxacin) and Vigamox (Moxifloxacin) in Killing Conjunctival Bacterial Flora Following a One-hour Application

This study has been withdrawn prior to enrollment.
Information provided by (Responsible Party):
Christopher Ta, Stanford University Identifier:
First received: April 25, 2007
Last updated: June 12, 2013
Last verified: June 2013
Topical ophthalmic antibiotics are common prescribed just prior to eye surgery to lower the risk of infection. Previous studies have suggested that antibiotics containing a preservative (Zymar) kill bacteria much quicker than those without a preservative (Vigamox). The purpose of this research is to compare how quickly to the two commonly prescribed antibiotics eliminate bacteria from the eye surface.

Condition Intervention
Conjunctical Flora
Drug: gatifloxacin, moxifloxacin

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Factorial Assignment
Masking: Single Blind
Primary Purpose: Prevention
Official Title: Prospective Randomized Comparison of Zymar(Gatifloxacin) and Vigamox (Moxifloxacin) in Killing Conjunctival Bacterial Flora Following a One-hour

Resource links provided by NLM:

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Antibiotic killing of conjunctival bacterial flora 1 hour after application

Enrollment: 0
Study Start Date: April 2007

Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age- older than 50 years of age
  • Diagnosis- Cataract or had cataract surgery

Exclusion Criteria:

  • Systemic or topical antibiotic treatment within 30 days
  • Use of systemic or topical steroids
  • Active ocular infection
  • Ocular surgery in the past 6 months
  • Allergy to fluoroquinolones
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00466570

Sponsors and Collaborators
Stanford University
Principal Investigator: Christopher Ta, MD Stanford University
  More Information

Responsible Party: Christopher Ta, Principal Investigator, Stanford University Identifier: NCT00466570     History of Changes
Other Study ID Numbers: 8924 
Study First Received: April 25, 2007
Last Updated: June 12, 2013
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Norgestimate, ethinyl estradiol drug combination
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Contraceptives, Oral, Combined
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Nucleic Acid Synthesis Inhibitors processed this record on October 25, 2016